Uroporphyrinogen III decarboxylase

From WikiMD's WELLNESSPEDIA

Uroporphyrinogen-decarboxylase

Uroporphyrinogen III decarboxylase is an enzyme that plays a crucial role in the heme biosynthesis pathway. It catalyzes the conversion of uroporphyrinogen III to coproporphyrinogen III by decarboxylating the four acetate groups to methyl groups. This reaction is essential for the production of heme, which is a vital component of hemoglobin, myoglobin, and various cytochromes.

Function[edit]

Uroporphyrinogen III decarboxylase is responsible for the fourth step in the heme biosynthesis pathway. The enzyme removes four carboxyl groups from uroporphyrinogen III, resulting in the formation of coproporphyrinogen III. This step is critical for the proper synthesis of heme, as it allows for the subsequent steps that lead to the production of protoporphyrin IX and ultimately heme.

Structure[edit]

The enzyme is a homodimer, meaning it consists of two identical subunits. Each subunit contains an active site where the decarboxylation reaction occurs. The structure of uroporphyrinogen III decarboxylase has been studied extensively using X-ray crystallography, revealing important details about its catalytic mechanism and substrate binding.

Clinical Significance[edit]

Deficiency or malfunction of uroporphyrinogen III decarboxylase can lead to a group of disorders known as porphyrias. One of the most well-known conditions associated with this enzyme is porphyria cutanea tarda (PCT), which is characterized by photosensitivity, skin fragility, and blistering. PCT is the most common type of porphyria and can be triggered by factors such as alcohol consumption, liver disease, and certain medications.

Related Enzymes[edit]

Uroporphyrinogen III decarboxylase is part of a larger family of enzymes involved in the heme biosynthesis pathway. Other key enzymes in this pathway include:

See Also[edit]

References[edit]


External Links[edit]


Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.